Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIa randomized double-blind placebo-controlled study of morphothiadine mesilate plus ritonavir added to nucleos(t)ide therapy in chronic hepatitis B
CTR20213273Phase 3Active
- Sponsor
- HEC Pharm
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mofesertib, ritonavir in Chronic Hepatitis B (CHB), sponsored by HEC Pharm. Started Dec 2021; status: active.
02
Drugs
mofesertibritonavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20213273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213273.